Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

41
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
41
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

39
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
39

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine learning-based classification of population affinity in two North Indian populations using morphological dental traits-Forensic implications.

Legal medicine (Tokyo, Japan)·2026
Same author

Human earprints in forensic identification: scientific foundations, classification methods, and legal implications.

Die Naturwissenschaften·2026
Same author

Coronary Artery Bypass Grafting to Acute Marginal Branch: Forgotten Coronary Artery.

Annals of thoracic surgery short reports·2026
Same author

Early predictors and outcomes of mechanical circulatory support use during single lung transplant for secondary pulmonary hypertension: A large single-center experience.

JHLT open·2026
Same author

Right Anterior Thoracotomy Versus Partial Sternotomy for Isolated Aortic Valve Replacement: A Propensity Analysis of Clinical Outcomes and Hospital Costs.

Medicina (Kaunas, Lithuania)·2026
Same author

Off-Pump Lung Transplantation: Key Surgical and Anesthetic Considerations.

Annals of thoracic surgery short reports·2026

Related Experiment Video

Updated: Sep 19, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K

Surgically implanted temporary ventricular assist pump - "Impella 5.5".

Akshay Chauhan1, Mikiko Senzai1, Sriram Vijayapuri1

  • 1Department of Cardiovascular Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19004 USA.

Indian Journal of Thoracic and Cardiovascular Surgery
|June 19, 2025
PubMed
Summary
This summary is machine-generated.

The Impella 5.5 left ventricular assist device offers short-term cardiac support for severe heart failure. Evidence confirms its efficacy in improving cardiac output and organ perfusion, despite potential risks.

Keywords:
Heart failureImpella 5.5Microaxial pump

More Related Videos

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.0K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K

Related Experiment Videos

Last Updated: Sep 19, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.0K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K

Area of Science:

  • Cardiology
  • Medical Devices
  • Mechanical Circulatory Support

Background:

  • Severe heart failure and cardiogenic shock necessitate advanced cardiac support.
  • The Impella 5.5 is a catheter-based left ventricular assist device designed for short-term mechanical support.
  • Its design offers advantages in ease of insertion and minimal afterload increase.

Purpose of the Study:

  • To provide a comprehensive analysis of the Impella 5.5 device.
  • To review its design, clinical applications, benefits, and challenges.
  • To reassess its role in treating severe heart failure and cardiogenic shock based on recent evidence.

Main Methods:

  • Review of clinical trials and real-world evidence.
  • Analysis of device design and surgical implantation strategies.
  • Assessment of patient outcomes and potential complications.

Main Results:

  • The Impella 5.5 effectively enhances cardiac output and organ perfusion.
  • Short-term support is linked to improved outcomes in cardiogenic shock.
  • Identified risks include bleeding, vascular complications, and hemolysis.

Conclusions:

  • Appropriate patient selection, surgical planning, and post-insertion management are crucial for Impella 5.5 use.
  • Further research is needed on long-term outcomes, cost-effectiveness, and technological advancements.
  • The Impella 5.5 plays a significant role in managing acute cardiac conditions.